Utility of Random Biopsies in Patients With Inflammatory Bowel Disease

Enrolling by invitation · Not applicable

Conditions studied: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis

In brief

The proposed study is a multicenter parallel group clinical trial that will include 821 evaluable patients per group who will be randomly assigned to either high definition white light colonoscopy (HDWLC) with targeted biopsies plus 2 random biopsies in 4 segments to assess for inflammation (limited biopsy strategy) or HDWLC with targeted biopsies plus 4 biopsies every 10 cm throughout the colon, at a minimum in all segments of the colon known to have been affected by IBD at any time, regardless of the extent of disease (random biopsy strategy). Participants will be followed until total proctocolectomy or the end of the study period to determine whether the two methods of surveillance colonoscopy are associated with detection of dysplasia or sessile serrated adenoma at follow-up colonoscopy. Follow-up via chart review may continue for up to 15 years from enrollment.

Key facts

Study ID

NCT06560021

Run by

Abramson Cancer Center at Penn Medicine

People needed

1642

Starts

2025-01-03

Expected to finish

2029-06-30

Last updated by the study team

2026-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of left-sided (greater than 15 cm of disease but not beyond the splenic flexure) or extensive (extending beyond the splenic flexure) ulcerative colitis or IBD-U or colonic Crohn's disease involving at least 1/3 of the colon (defined as 2 segments of the remaining colon; segments include right colon, transverse colon, left colon and rectum).
• Disease duration must meet one of the following criteria:
• onset of symptoms of IBD at least 8 years prior
• diagnosis of IBD at least 8 years prior
• diagnosis of IBD for any duration if other risk factors for colon cancer are present including: concomitant diagnosis of primary sclerosing cholangitis, personal history of dysplasia, sessile serrated adenoma or right sided hyperplastic polyps greater than 10mm in diameter, or a family history of colon cancer in a first degree relative or two second degree relatives.
• Scheduled to undergo colonoscopy as part of routine care
• At least one indication for the index colonoscopy must be to perform dysplasia surveillance.

You may not qualify if…

• Any condition that the endoscopist feels is a contraindication to random biopsies
• History of visible (high or low grade) dysplasia not completely removed
• History of sessile serrated adenoma not completely removed
• History of colorectal cancer
• Any condition for which the endoscopist feels that pancolonic contrast or virtual chromoendoscopy is mandatory
• Less than 2 segments of the remaining colon have ever been involved with IBD
• Colonoscopy* in the last 11 months unless the colonoscopy:
• was determined by the endoscopist to be insufficient for dysplasia surveillance and,
• did not include a diagnosis of dysplasia or sessile serrated adenoma. *Does not include sigmoidoscopy
• Inability to provide informed consent

Where it is running

• University of Alabama Birmingham — Birmingham, Alabama, United States
• University of California, Los Angeles — Los Angeles, California, United States
• Scripps Health — San Diego, California, United States
• University of Colorado — Aurora, Colorado, United States
• Mayo Clinic Jacksonville — Jacksonville, Florida, United States
• University of Miami — Miami, Florida, United States
• AdventHealth — Orlando, Florida, United States
• Northwestern University — Chicago, Illinois, United States
• Mercy Medical Center — Baltimore, Maryland, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Mayo Clinic Rochester — Rochester, Minnesota, United States
• NYU Langone Health — New York, New York, United States
• Icahn School of Medicine at Mount Sinai — New York, New York, United States
• University of Rochester — Rochester, New York, United States
• University of North Carolina — Chapel Hill, North Carolina, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• University of Pittsburgh — Pittsburgh, Pennsylvania, United States
• Allegheny Health Network — Pittsburgh, Pennsylvania, United States
• Houston Methodist Hospital — Houston, Texas, United States
• University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.